Navigation Links
Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
Date:2/25/2008

Products and Pipeline to Enhance Galderma's Position in Dermatology

LAUSANNE, Switzerland and NEWTOWN, Pa., Feb. 26 /PRNewswire/ -- Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, and CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI) today announced a definitive agreement pursuant to which Galderma's U.S. holding company, Galderma Laboratories, Inc., will acquire all of the outstanding shares of CollaGenex at a price of $16.60 per share in cash, representing approximately $420 million for the equity of CollaGenex. The transaction was unanimously approved by the boards of directors of Galderma and CollaGenex.

"Galderma is committed to provide innovative medical solutions to dermatology patients and physicians across the globe," said Humberto C. Antunes, Chief Executive Officer of Galderma. "CollaGenex' innovative products complement and enhance Galderma's portfolio. We admire the accomplishments of CollaGenex' employees and believe our combined organizations will be even better positioned to serve patient's needs. This transaction should be neutral to Galderma's net income in 2008 and accretive as of 2009."

CollaGenex launched Oracea(R), the first FDA-approved systemic product indicated for the treatment of rosacea, in July 2006. CollaGenex is also developing Col-118, an innovative product for the treatment of the erythema associated with rosacea. If approved, Col-118 would be the first effective treatment for erythema. In addition, CollaGenex is developing a product with the potential to provide added benefits for the treatment of psoriasis.

"The immediate implication for the U.S. market is very positive," said Albert Draaijer, President of Galderma's U.S. operations. "Coll
'/>"/>

SOURCE Galderma Pharma S.A.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
2. Spiritual Healer/Psychic-Medium Reaches International Status!
3. EMBL reaches north
4. AK Steel Reaches VEBA Health Care Settlement With Middletown Works Retirees
5. Sun Safety Awareness Reaches New Heights at Plano Hot Air Balloon Festival
6. 40 Days for Life Reaches Halfway Point; Planned Parenthood Now in Crisis Mode
7. Blue Cross of California Reaches Out to Members Impacted by Southern California Fires
8. Free Site Offering Patient-Physician Dialog Reaches Milestone
9. Sharp HealthCare Foundation Reaches $50 Million Goal
10. Nyer Medical Group Reaches Agreement to Acquire Minority Interest in Pharmacy Chain Subsidiary
11. MB Software Corporation Reaches Agreement with Keystone Equity Partners

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)... promotes self-assurance, research finds , ...r may have been right when she told you to sit up ...could make you feel more confident about your thou...p straight gives a good impression to other people...chology professor at Ohio State University, said i...
(Date:11/8/2009)...ire-USNewswire/ -- Speaker Nancy Pelosi and Democr... House passage of H.R. 3962, the Affordable Health...of 220 to 215. Below are the Speaker,s opening re...ceived a call from the President of the United Sta...ctory for the American people. I thank the Preside...
(Date:11/8/2009)...drying of biopharmaceuticals to be available at th... , Toronto, ON (PRWEB) Nov... of Therapure Biopharma Inc. today announced that ...le pharmaceutical grade freeze dryer and expects t...ion) available for contract manufacturing of bioph...
(Date:11/8/2009)... the battle is won," said Dr. Charmaine Yoest. ,...In a vote of 240-194, the Stupak-Ellsworth-Pitts-K...bit abortion mandates and funding in HR 3962 passe...ife Action President and CEO Dr. Charmaine Yoest s...or the pro-life Americans across this country who ...
(Date:11/8/2009)... H.R. 3961 to Secure the Stability of Medicare ,...tement Attributable to: J. James Rohack, M.D., Pre... http://www.newscom.com/cgi-bin/prnh/20081209/AM...House health reform bill, which will help improve ...calls for swift passage of H.R. 3961 to secure the...
Breaking Medicine News(10 mins):Health News:Good Posture May Inspire Confidence 2Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2
...ame of a Class 10 correspondence course student in...iled to do, an official said Saturday//. The ...d 22 students of various private and government hi...at had three others with the same score. The boy h...
...sights about how a bacterium uses different recept...a are sensitive to minute changes in environments ...of 1 drop in a pool of 1,000 drops. New Corn...perative lattice on a bacterium's surface to ampli...
... essential for proper embryo development and disor...h defects such as cleft palate, spina bifida, repo...ffort of the University of Colorado, Health Scienc...Critical for Downregulation of E-Cadherin During M...
...announced a warning on the usage of Triaminic vapo...serious effects //they could have if accidentally ...h authorities have explained that life-threatening...ised as a cough suppressant for kids 2 years of ag...
...fter eating (traditionally called European siesta)... happening due to changes in glucose levels//. ...y in humans and as well as in animals become switc...sed from the neurons, whose action is focused on t...
...er treatment drug has proved so well in the drug t...ght be made //available to patients in the late st...the regulators. It is speculated that Europe... claim that unlike Roche's $1.8bn-a-year drug, Her...
Other Medicine News:Health News:Study Highlights How Bacteria Respond To Changes In Environment 2Health News:GSK’s New Anticancer Drug A Huge Success In Drug trail 2
(Date:11/6/2009)...TA, Nov. 6 GeoVax Labs,...e Company"), an Atlanta-based, biopharmaceutical c...ed by HIV-1 (Human Immunodeficiency Virus) and oth...arter 2009 financial results and provided an opera...ent and Chief Executive Officer commented, "We are...
(Date:11/6/2009)...IEGO, Nov. 6 California American W...s "No Drugs Down the Drain" week for its San Diego...n sponsored by public and private agencies alike t...l pollution in our source water supplies. ,, Ca...rs are encouraged to drop off expired or unwanted ...
(Date:11/5/2009)...IEGO, Nov. 5 Althea Technologies,...acturing services for biopharmaceutical products a...velopment to the company,s platform of services, w...ames Matsuura, Director of Formulation Development...ation and analytical scientists, along with new la...
Breaking Medicine Technology:GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29 2009 5323 1Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29 2009 5323 2Hutchinson Center scientists net 2416 7 million for stem cell research 59136 1Hutchinson Center scientists net 2416 7 million for stem cell research 59136 2Elderly immune system needs a boost 59134 1Elderly immune system needs a boost 59134 2
... 12 Boston,Scientific Corporation (NYSE: BSX ) t...7,500 patients from its TAXUS ARRIVE 1 and 2 regis...ce of the TAXUS(R) Express2(TM),Paclitaxel-Eluting...,two-year pooled ARRIVE data showed that the TAXUS...h diabetes as effectively as in patients without,d...
...entific,Corporation (NYSE: BSX ) today announced ...ss announcements at the Cardiovascular Research Fo...rdiovascular Therapeutics (TCT),scientific symposi..., D.C., Boston Scientific will be announcing a wi...R) Express2(TM) and second-generation TAXUS(R),Lib...
Other Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
Giardia lamblia II EIA
Medicine Products: